JAK3 and psoriatic arthritis: Tofacitib, which targets JAK3 as well as both JAK1 and JAK2, and is approved for use in rheumatoid and psoriatic arthritis and ulcerative colitis [71], has been shown to be highly effective in cell line models of various JAK3 GOF mutations [26,42,73,74].